Zobrazeno 1 - 10
of 2 176
pro vyhledávání: '"Endocrine resistance"'
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 1189-1204 (2024)
Jiafeng Lu,1,* Zhaoyan Li,2,* Xingjing Liu,2 Bin Xu,1 Weiyu Zhang2 1Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 2Department of Traditional Chinese Medicine, Ruijin Hospital, S
Externí odkaz:
https://doaj.org/article/dbfae30de7a340babeea13b20f45fddb
Publikováno v:
Zhongguo aizheng zazhi, Vol 34, Iss 6, Pp 537-547 (2024)
Background and purpose: Silent information regulator proteins (sirtuins, SIRT) are a class Ⅲ histone deacetylases with nicotinamide adenine dinucleotide (NAD+) as coenzyme. YME1 like 1 ATPase (YME1L1) is essential for the maintenance of mitochondri
Externí odkaz:
https://doaj.org/article/1f3307745bd349eebb666dad2693413b
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Around 75% of breast cancer (BC) patients have tumors expressing the predictive biomarker estrogen receptor α (ER) and are offered endocrine therapy. One-third eventually develop endocrine resistance, a majority with retained ER expression.
Externí odkaz:
https://doaj.org/article/1be00ef29da948768b38964f3c8ef370
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 181-197 (2024)
Meixi Ye,1 Hao Xu,1,* Jinhua Ding,2,* Li Jiang3 1The Affiliated Lihuili Hospital, Ningbo University, Ningbo, 315040, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 3150
Externí odkaz:
https://doaj.org/article/60ae63738642489fb6fd0253a8f660de
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Fibroblast Growth Factor Receptors (FGFRs) play a significant role in Estrogen Receptor-positive (ER+) breast cancer by contributing to tumorigenesis and endocrine resistance. This review explores the structure, signaling pathways, and implications o
Externí odkaz:
https://doaj.org/article/c77f9cfa9e71427b96f72ba33a0f3933
Autor:
Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, Alberto Malovini, Pietro Lapidari, Barbara Tagliaferri, Ludovica Mollica, Cristina Maria Teragni, Chiara Barletta, Laura Deborah Locati, Federico Sottotetti
Publikováno v:
Drugs in Context, Vol 13, Pp 1-11 (2024)
Background: Breast cancer is the most frequent tumour worldwide, and the HR+/HER2– subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represen
Externí odkaz:
https://doaj.org/article/fb58aea72e3a49eb97cf2df9cc8db001
Autor:
Michael K. McGrath, Ali Abolhassani, Luke Guy, Ahmed M. Elshazly, John T. Barrett, Nahid F. Mivechi, David A. Gewirtz, Patricia V. Schoenlein
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer diagnosed annually in the US with endocrine-based therapy as standard-of-care for this breast cancer subtype. Endocrine therapy includes treatment with antiestrogens, suc
Externí odkaz:
https://doaj.org/article/3cca55924e8440b18214f9cbedfcc9fd
Autor:
Léa Clusan, Frederic Percevault, Emmanuelle Jullion, Pascale Le Goff, Christophe Tiffoche, Tamara Fernandez‐Calero, Raphaël Métivier, Monica Marin, Farzad Pakdel, Denis Michel, Gilles Flouriot
Publikováno v:
Molecular Oncology, Vol 17, Iss 7, Pp 1302-1323 (2023)
Oestrogen receptor‐alpha (ERα) positivity is intimately associated with the development of hormone‐dependent breast cancers. A major challenge in the treatment of these cancers is to understand and overcome the mechanisms of endocrine resistance
Externí odkaz:
https://doaj.org/article/a18b6851c3da4c85afbc589534d40b27